Karyopharm Therapeutics, Inc. (KPTIQ)
0.0255
+0.01
(+45.71%)
USD |
OTCM |
Nov 12, 16:00
Karyopharm Therapeutics Free Cash Flow (Quarterly) : -24.93M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -24.93M |
| March 31, 2026 | -22.73M |
| December 31, 2025 | -11.83M |
| September 30, 2025 | -5.86M |
| June 30, 2025 | -18.70M |
| March 31, 2025 | -38.98M |
| December 31, 2024 | -25.76M |
| September 30, 2024 | -19.45M |
| June 30, 2024 | -38.50M |
| March 31, 2024 | -43.92M |
| December 31, 2023 | -18.58M |
| September 30, 2023 | -29.53M |
| June 30, 2023 | -25.70M |
| March 31, 2023 | -18.91M |
| December 31, 2022 | -26.84M |
| September 30, 2022 | -28.41M |
| June 30, 2022 | -35.14M |
| March 31, 2022 | -59.28M |
| December 31, 2021 | 25.77M |
| September 30, 2021 | -29.96M |
| June 30, 2021 | -55.75M |
| March 31, 2021 | -52.89M |
| December 31, 2020 | -30.75M |
| September 30, 2020 | -44.31M |
| June 30, 2020 | -40.29M |
| Date | Value |
|---|---|
| March 31, 2020 | -45.02M |
| December 31, 2019 | -39.54M |
| September 30, 2019 | -36.61M |
| June 30, 2019 | -48.20M |
| March 31, 2019 | -66.67M |
| December 31, 2018 | -49.26M |
| September 30, 2018 | -39.16M |
| June 30, 2018 | -38.02M |
| March 31, 2018 | -35.03M |
| December 31, 2017 | -5.593M |
| September 30, 2017 | -21.76M |
| June 30, 2017 | -21.72M |
| March 31, 2017 | -24.71M |
| December 31, 2016 | -20.02M |
| September 30, 2016 | -20.33M |
| June 30, 2016 | -20.90M |
| March 31, 2016 | -23.20M |
| December 31, 2015 | -20.88M |
| September 30, 2015 | -25.47M |
| June 30, 2015 | -28.70M |
| March 31, 2015 | -20.40M |
| December 31, 2014 | -12.87M |
| September 30, 2014 | -18.52M |
| June 30, 2014 | -12.21M |
| March 31, 2014 | -10.69M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Heron Therapeutics, Inc. | -0.896M |
| Tonix Pharmaceuticals Holding Corp. | -39.43M |
| Minerva Neurosciences, Inc. | -8.150M |
| Corbus Pharmaceuticals Holdings, Inc. | -21.25M |
| Ocugen, Inc. | -15.89M |